Randomized double blind placebo-controlled phase II study on the effects of EA-230 on the innate immune response following on-pump cardiac surgery
Latest Information Update: 10 Feb 2022
At a glance
- Drugs EA 230 (Primary)
- Indications Acute kidney injury; Systemic inflammatory response syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms EASI
- Sponsors Exponential Biotherapies
- 31 Aug 2018 Status changed from active, no longer recruiting to completed.
- 25 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
- 25 Jun 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018.